Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
27.00
+0.31 (1.16%)
At close: Jun 26, 2026, 4:00 PM EDT
27.09
+0.09 (0.32%)
After-hours: Jun 26, 2026, 7:23 PM EDT
Arcutis Biotherapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Arcutis Biotherapeutics stock have an average target of 34.22, with a low estimate of 31 and a high estimate of 36. The average target predicts an increase of 26.74% from the current stock price of 27.00.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Arcutis Biotherapeutics stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho Securities | Mizuho Securities | Buy Reiterates $35 | Buy | Reiterates | $35 | +29.63% | Jun 3, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $35 | Buy | Maintains | $35 | +29.63% | May 26, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $34 | Buy | Reiterates | $34 | +25.93% | May 11, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $35 → $34 | Buy | Maintains | $35 → $34 | +25.93% | May 7, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $35 | Buy | Maintains | $35 | +29.63% | May 7, 2026 |
Financial Forecast
Revenue This Year
497.11M
from 376.07M
Increased by 32.19%
Revenue Next Year
645.81M
from 497.11M
Increased by 29.91%
EPS This Year
0.17
from -0.13
EPS Next Year
1.13
from 0.17
Increased by 582.83%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 501.3M | 702.1M | |
| Avg | 497.1M | 645.8M | |
| Low | 490.6M | 617.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 33.3% | 41.2% | |
| Avg | 32.2% | 29.9% | |
| Low | 30.5% | 24.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | 0.17 | 1.13 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | 582.8% | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.